Price T Rowe Associates Inc Biogen Inc. Transaction History

Price T Rowe Associates Inc

$836 Billion
Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in Biogen Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,011,411 shares of BIIB stock, worth $350 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

2,011,411

Previous 1,589,629 26.53%

Holding current value

$350 Million

Previous $343 Million 36.03%

% of portfolio

0.06%

Previous 0.04%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $80.4 Million - $99.8 Million	421,782 Added 26.53%	2,011,411 $466 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $17.2 Million - $21.8 Million	81,283 Added 5.39%	1,589,629 $343 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $76.8 Million - $92.4 Million	344,816 Added 29.64%	1,508,346 $390 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $8.84 Million - $9.97 Million	34,888 Added 3.09%	1,163,530 $299 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $264 Million - $305 Million	-959,714 Reduced 45.96%	1,128,642 $321 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $177 Million - $202 Million	691,843 Added 49.54%	2,088,356 $581 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $34.8 Million - $42.3 Million	-138,002 Reduced 8.99%	1,396,513 $387 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $98 Million - $135 Million	503,584 Added 48.85%	1,534,515 $410 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $8.45 Million - $10 Million	-45,038 Reduced 4.19%	1,030,931 $210 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $10.7 Million - $13.5 Million	-55,388 Reduced 4.9%	1,075,969 $227 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $146 Million - $188 Million	-652,779 Reduced 36.59%	1,131,357 $271 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $48.6 Million - $63.3 Million	171,573 Added 10.64%	1,784,136 $505 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $42.6 Million - $68.3 Million	-164,608 Reduced 9.26%	1,612,563 $558 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $21.8 Million - $25.6 Million	89,873 Added 5.33%	1,777,171 $497 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $399 Million - $600 Million	1,687,298 New	1,687,298 $413 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Biogen Inc. Transaction History